Hormone Receptor-Positive Breast Cancer Sensitive to Pembrolizumab: Evidence of the Pathogenicity of the MLH1 Variant 1835del3
J Natl Compr Canc Netw. 2023 Aug 29:1-7. doi: 10.6004/jnccn.2023.7035. Online ahead of print.ABSTRACTA woman with estrogen/progesterone receptor-positive, ERBB2-negative metastatic breast cancer developed progressive disease despite treatment with multiple hormonal and chemotherapeutic modalities. She carried a germline variant of MLH1 (1835del3), also known as c.1835_1837del and v612del, the pathogenicity of which has not been conclusively determined. MLH1 staining was not seen on immunohistochemical staining of her tumor tissue. The patient experienced a >5-year dramatic response to 4 doses of pembrolizumab. Family st...
Source: Journal of the National Comprehensive Cancer Network : JNCCN - August 29, 2023 Category: Cancer & Oncology Authors: Henry G Kaplan Jeffrey R Whiteaker Brianna Nelson Richard G Ivey Travis D Lorentzen Uliana Voytovich Lei Zhao David J Corwin Robert Resta Amanda G Paulovich Source Type: research
Development of an Electronic Health Record-Based Clinical Decision Support Tool for Patients With Lynch Syndrome
CONCLUSION: We have successfully developed an EHR-based CDS tool to promote guideline-recommended cancer risk management among patients with LS.PMID:37639653 | DOI:10.1200/CCI.23.00024 (Source: Clinical Colorectal Cancer)
Source: Clinical Colorectal Cancer - August 28, 2023 Category: Cancer & Oncology Authors: Kelsey S Lau-Min Joseph Bleznuck Colin Wollack Danielle B McKenna Jessica M Long Anna P Hubert Mariah Johnson Shavon E Rochester Gillain Constantino Christina Dudzik Abigail Doucette Kirk Wangensteen Susan M Domchek Jeffrey Landgraf Jessica Chen Katherine Source Type: research
